HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

Annals of the Rheumatic Diseases

Volumn 58, Issue 10, 1999, Pages 598-610

  Ringrose, J H ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; HLA B27 ANTIGEN;

AMINO ACID SEQUENCE; AUTOIMMUNITY; CROSS REACTION; HUMAN; IMMUNOPATHOGENESIS; KLEBSIELLA PNEUMONIAE; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; T LYMPHOCYTE ACTIVATION;

EID: 0032833157     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.10.598     Document Type: Review

References (107)

1. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European spondyloarthropathy study group preliminary criteria for the classification of spondy-loarthropathy. Arthritis Rheum 1991;34:1218-27.
2. Aho K, Ahvonen P, Lassus A, Silvers K, Tilikainen A. HL-A antigen 27 and reactive arthritis. Lancet 1973;ii:157.
3. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;i:904-7.
4. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1997;288:704-6.
5. Brewerton DA, Caffrey MFP, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. Lancet 1973; ii:996-8.
6. Aho K, Ahvonen P, Lassus A, Sievers K, Tiilikainen A. HLA-B27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease. Arthritis Rheum 1974;17:521-6.
7. Sieper J, Braun J. Pathogenesis of spondyloarthropathies. Arthritis Rheum 1915;38:1547-51.
8. Benjamin R, Parham P. Guilt by association. Immunol Today 1990;11:137-42.
9. Brown M, Wordsworth P. Predisposing factors to spondyloarthropathies. Curr Opin Rheumatol 1997;9:308-14.
10. Ebringer A. Ankylosing spondylitis is caused by Klebsiella. Evidence from immunogeneric, microbiologic, and serologic studies. Rheum Dis Clin North Am 1992;18:105-21.
11. Fujinami RS. Molecular mimicry. In: Peter JB, Shoenfeld Y. eds. Autoantibodies. Amsterdam: Elsevier Science, 1996: 507-12.
12. Damian KT. Molecular mimicry: antigen sharing by parasite and host and its consequences. American Naturalist 1964; 98:129-49.
13. Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: cross-reaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci 1983;80:2346-50.
14. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of mychn basic protein and virus: mechanism for autoimmunity. Science 1985;230:1043-5.
15. Blaauw I, van der Linden S, Nohlmans L. An increased prevalence of anti-Borrclia burgdorferi antibodies in ankylosing spondylitis: fact or artefact? Scand J Rheumatol 1990;87(suppl 2):148.
16. Scofield RH, Warren WL, Koelsch G, Harley JB. A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. Proc: Natl Acad Sci 1993;90:9330 4.
17. Scofield RH, Kurien B, Gross T, Warren WI, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacterial implications for spondyloarthropathy. Lancet 1995; 345:1542 4.
18. Davenport MB The promiscuous B27 hypothesis. Lancet 1995; 346:500-1.
19. Parham P. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol Rev 1996; 154: 137-54.
20. Schwimmbeck PL, Oldstone MB. Autoimmune pathogenesis for ankylosing spondylitis (AS) and Reiter's syndrome (RS): autoantibodies against an epitope shared by HLA B27 and Klebsiella pneumoniac nitrogenase in sera of HLA B27 patients with AS and RS. Trans Assoc Am Phys 1987; 100:28-39.
21. Ebringer A. The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis. Br J Rheumatol 1983; 22:53-66.
22. Kuberski TT, Morse HG, Rate RG, Bonnel MD. Increased recovery of Klebsiella from the gastrointestinal tract of Reiter's syndrome and ankylosing spondylitis patients. Br J Rheumatol 1983;22:85-90.
23. Welsh J, Avakian H, Cowling P, Ebringer A, Wooley P, Panayi G, et al. Ankylosing spondylitis, HLA-B27 and Klebsiella. I. Cross- reactivity studies with rabbit antisera. Br J Exp Pathol 1980; 61:85-91.
24. Avakian H, Welsh J, Ebringer A, Entwistle CC, Ankylosing spondylitis, HLA-B27 and Klebsiella- IL. Cross-reactivity studies with human tissue typing sera. Br J Exp Pathol 1980;61:92-6.
25. Trull AK, Panayi GS. Further observations on Klebsiella molecular cross-reactivity in HLA-B27 positive persons. J Rheumatol 1985;12:1024.
26. Geczy AF, Prendergast JK, McGuigan LE, Upfold LJ, Sullivan JS. Cross-reactivity of anti-Klebsiella K43 BTS I serum and lymphocytes of patients with ankylosing spondylitis: antipodean curiosity? Lancet 1985;i:1169.
27. Beukelman CJ, van Leeuwen A, Aerts PC, van Kregten E, van Bree S, van Rood JJ, et al. Rabbit antisera to enterobacteriaccae isolated from HLA-B27 positive pntients with ankylosing spondylitis (AS) are lytic for the mononuclear cells of AS patients. Br J Rheumatol 1988;27 (suppl 2):58-60.
28. Baines M, Ebringer A, Avakian H, Samuel D, James DC. The use of enzyme immunoassay (EIA) and radiobinding assay to investigate the cross-reactivity of Klebsiella antigens and HLA B27 in ankylosing spondylitis patients and healthy controls. Scand J Rheumatol 1990;19:341 9.
29. Wakefield D, Easter J, Robinson P, Graham D, Penny R. Chlamydial antibody crossreactivity with peripheral blood mononuclear cells of patients with ankylosing spondylitis: the role of HLA B27. Clin Exp Immunol 1986;63:49-57.
30. Geczy AF, Yap J. HLA-B27, Klebsiella, and ankylosing spondylitis. Lancet 1979;i:719-20.
31. Seager K, Bashir HV, Geczy AF, Edmonds J, de Vere-Tyndall A. Evidence for a specific B27-associated cell surface marker on lymphocytes of patients with ankylosing spondylitis. Nature 1979;277:68-70.
32. Geczy AF, Alexander K, Bashir HV, Edmonds J. A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component. Nature 1980;283: 782 4.
33. Cameron FH, Russell PJ, Easter JF, Wakefield D, March L. Failure of Klebsiella pneumoniae antibodies to cross-react with peripheral blood mononuclear cells from patients with ankylosing spondylitis. Arthritis Rheum l987;30:300-5.
34. Georgopoulos K, Dick WC, Goodacre JA, Pain RH. A reinvestigation of the cross-reactivity between Klebsiella and HLA-B27 in the actiology of ankylosing spondylitis. Clin Exp Immunol 1985;62:662-71.
35. Inman RD, Chiu B, Johnston ME, Falk J. Molecular mimicry in Reiter's syndrome: cytotoxicity and ELISA studies of HLA-microbial relationships. Immunology 1986:58:501-6.
36. Roudier J, De Montelos H, Thouvenot D, Chomel JJ, Guillermet FN, Betuel H. Absence of cross-reaction between HLA B27 and yersinia enterocolitica or chlamydia trachomatis in reactive arthritis and ankylosing spondylitis. Clin Rheumatol 1985;4:487.
37. Geczy AF, McGuigan LE, Sullivan JS, Edmonds JP. Cytotoxic T lymphocytes against disease-associated determinant(s) in ankylosing spondylitis. J Exp Med 1986;164: 932-7.
38. Gao XM, Wordsworth P, McMichacl AJ, Kyaw MM, Seifert M, Rees D, et al. Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 1996;1443-50.
39. Archer JR, Whelan MA, Badakere SS, McLean IL, Archer IVJ, Winrow VR. Effect of a free sulphydryl group on expression of HLA-B27 specificity. Scand J Rheumatol 1990;87 (suppl):44-50.
40. van Bohemen CG, Grumer FC, Zanen HC. Identification of HLA-B27M1 and -M2 cross-reactive antigens in Klebsiella, Shigella and Yersinia. Immunology 1984;52:607-10.
41. Raybourne RB, Bunning VK, Williams KM. Reaction of anti-HLA-B monoclonal antibodies with envelope proteins of Shigella species. Evidence for molecular mimicry in the spondyloarthropathies. J Immunol 1988;140:3489-95.
42. Kono DH, Ogasawara M, Effros RB, Park MS, Waldord RL, Yu DT, Ye-1, a monoclonal antibody that cross-reacts with HLA-B27 lymphoblastoid cell lines and an arthritis causing bacteria. Clin Exp Immunol 1985;61:503-8.
43. Feltkamp TEW, The mystery of autoimmune diseases. In: Shoenfeld Y, ed. The decade of autoimmunity. Amsterdam: Elsevier Science BV, 1999.
44. Silverstein AM. A history of immunology. San Diego: Academic Press, 1989:161-89.
45. Berneman A, Ternynck T, Avrameas S. Natural mouse IgG reacts with self antigens including molecules involved in the immune response. Eur J Immunol 1992;22:625-33.
46. Cohen IR, Cooke A. Natural autoantibodies might prevent autoimmune disease, Immunol Today 1986;7:363-4.
47. Ivanyi P, Leupers T, van Mourik P. Naturally occurring cytotoxic human antibodies recognize H-2- controlled murine lymphocyte antigens. Proc Natl Acad Sci 1983;80: 4479-83.
48. Avrameas S, Ternynck T. Natural autoantibodies: the other side of the immune system. Res Immunol 1995;146:235-48.
49. Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto- and polyreactivities of normal human sera. Mol Immunol 1993;30:1499-510.
50. Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol 1990;145:3807-13.
51. Rose NR. The use of autoantibodies. In: Peter JB, Shoenfeld Y. eds. Autoantibodies Amsterdam: Elsevier Science, 1996: xxvii-xxix.
52. Feltkamp TEW. Auto-immuuziekten. Leiden: Stafleu's wetenschappelijke uitgeversmaatschappij nv, 1971:11-2.
53. Schwartz RS. Autoimmunity and autoimmune diseases. In: Paul WE, ed. Fundamental immunology. New York: Raven Press, 1993:1033-97.
54. Talal N. Autoimmunity and sex reviseted. Clin Immunol Immunopathol 1989;53:355.
55. 2-microglobulin J Rheumatol 1994;21:670-4.
56. Handley HH, Yu J, Yu DT, Singh B, Gupta RS, Vaughan JH. Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL. Clin Exp Immunol 1996; 103:429-35.
57. Juanola X, Mateo L, Domenech P, Bas J, Contreras N, Nolla JMXR-ED. Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. J Rheumatol 1995;22: 1891-3.
58. Vasey FB, Kinsella TD. Increased frequency of leukocytereactive, antinuclear antibody in patients with ankylosing spondylitis. J Rheumatol 1977;4:158-64.
59. Kinsella TD, Miller J, Grofton JP, Vasey FB. Population studies of leukocyte-reactive antinuclear antibody and HLA antigens. Rheumatol Int 1981:103-5.
60. Tani Y, Sato H, Tanaka N, Mori K, Doida Y, Hukuda S. Serum IgA1 and IgA2 subclass antibodies against collagens in patients with ankylosing spondylitis. Scand J Rheumatol 1997;26:380-2.
61. Tani Y, Sato H, Hukuda S. Autoantibodies to collagens in Japanese patients with ankylosing spondylitis. Clin Exp Rheumatol 1997;15:295-7.
62. Lakomek HJ, Plomann M, Specker C, Schwochau M. Ankylosing spondylttis: an autoimmune disease? Ann Rheum Dis 1991;50:776-81.
63. Isenberg DA, Feldman R, Dudency C, Konikoff F, Jones D, Ebringer AXSY. A study of antipolynucleotide antibodies, anti-Klebsiella (K30) antibodies and anti-DNA antibody idiotypes in ankylosing spondylitis. Br J Rheumatol 1987;26:168-71.
64. Buchanan RR, Wardlaw JR, Riglar AG, Littlejohn GO, Miller MH. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol 1989;16: 757-61.
65. MacSween RN, Dalakos TK, Jasani MK, Wilson ME, Boyle JA, Buchanan WWXGRB. Antinuclear factors in synovial fluids. lancet 1967;i:312-14.
66. Pitkeathly DA, Taylor G. Antinuclear factor in rheumatoid arthritis and related diseases. Ann Rheum Dis 1967;26: 1-9.
67. Ritchie RF. The clinical significance of titered antinuclear antibodies. Arthritis Rheum 1967;10:544-52.
68. Rosenberg JN, Johnson GD, Holborow EJ. Antinuclear antibodies in ankylosing spondylitis, psoriatic arthritis, and psoriasis. Ann Rheum Dis 1979;38:526-8.
69. Wang JY, Yeh HY, Tu ST, Chen AC. Immunoiogical study in three families of juvenile ankylosing spondylitis. Acta Paediatr Sin 1992:33:191-9.
70. Schwimmbeck PL, Yu DT, Oldstone MB. Autoantibodies to HLA B27 in the sera HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987;166:173-81.
71. Schwimmbeck PL, Oldstone MB. Molecular mimicry between human leukocyte antigen B27 and Klebsiella. Consequences for spondyloarthropathies. Am J Med 1988; 85:51-3.
72. Tani Y, Tiwana H, Hukuda S, N'ishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1997;24:109-14.
73. Fielder M, Pirt SJ, Tarpey. I, Wilson C, Cunningham P, Ettelaic CXBA, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulunasc of Klebsiella pneumoniae. FEBS Lett 1995;369:243-8.
74. Tsuchiya N, Husby G, Williams RC Jr. Studies of humoral and cell-mediated immunity to peptides shared by HLA-27.1 and Klebsiella pneumoniae nitrogenase in ankylosing spondylitis. Clin Exp Immunol 1989;76:354-60.
75. Tsuchiya N, Husby G, Williams RC Jr. Antibodies to the peptide from the plasmid-coded Yersinia outer membrane protein (YOP1) in patients with ankylosins spondylitis. Clin Exp Immunol 1990;82:493-8.
76. Cavender DE, Ziff M. Absence of Antienterobacteriaceae and anti-HLA-B27 antibodies in mitogen stimulated cultures of lymphocytes from patients with Reiter's syndrome and ankylosing spondylitis.. J Rheumatol 1988; 15:315-20.
77. Ewing C, Ebringer R, Tribbick G, Geysen HM. Antibody activity in ankylosing spondylitis sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 181-199). J Exp Med 1990; 171: 1635-47.
78. de Vries DD, Dekker-Sacys AJ, Gyodi E, Bohm U, Ivanyi P. Absence of autoantibodies to peptides shared by HLA-B27.5 and Klebsiella pneumoniae nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome. Ann Rheum Dis 1992;51:783-9.
79. Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G. HLA-B27-derived peptides as autoantigens for T Imphocytes in ankylosing spondylitis. Arthritis Rheum 1997;40:2047-54.
80. Kellner H, Wen J, Wang J, Raybourne RB, Williams KM, Yu DT. Serum antibodies from patients with ankylosing spondylitis and Reiter's syndrome are reactive with HLA-B27 cells transfected with the Mycobacterium tuberculosis hsp60 gene. Infect Immun 1994; 62:484-91.
81. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. lancet 1993;342:646-50.
82. Williams KM, Hirofuji T, Raybourne RB, Shook DL, Trucksess MW, Yu DT. Synthetic oligonucleotide probes complementary to the HLA-B variable region hybridize with Klebsiella pneumoniae. Microb Pathogen 1989;6: 277-86.
83. Winrow VR, Archer JR, Mitchell DJ. Regarding the ankylosing spondylitis/Klebsiella/HLA-B27 problem: more inconclusive proof. Arthritis Rheum 1988;31:453-4.
84. Tsuchiya N, Husby G, Williams RC Jr, Stieglitz H, Lipsky PE, Inman RD. Autoantibodies to the HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis-associated Shigella plasmid. J Clin Invest 1990;86:1193-203.
85. Lahesmaa R, Skurnik M, Vaara M, Leirisalo-Repo M, Nissila M, Granfors K, et al. Molecular mimickry between HLA B27 and Yersinia, Salmonella, Shigella and Kiebsiella within the same region of HLA alpha 1- helix. Clin Exp Immunol 1991;86:399-104.
86. Stieglitz H, Lipsky P. Association between reactive arthritis and antecedent infection with Shigella flexneri carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope. Arthritis Rheum 1993;36:1387-91.
87. Lahesmaa R, Skurnik M, Granfors K, Mottonen T, Saario R, Toivanen AXTP. Molecular mimicry in the pathogenesis of spondyloarthropathies. A critical appraisal of cross-reactivity between microbial antigens and HLA-B27. Br J Rheumatol 1992;31:221-9.
88. Ohno S. Many peptide fragments of alien antigens are homologous with host proteins, Unis canalizing T-cell responses. Proc Natl Acad Sci 1991;88:3065-8.
89. Roudier C., Auger I., Roudier J. Molecular mimicry reflected through database screening: serendipity or survival strategy? Immunol Today. 1996;17:357-8
90. Kalovidouris AE, Johnson RL. Cellular immunity in ankylosing spondylitis. Lack of response to spinal tissue antigens. J Rheumatol 1983:10:98-101.
91. Thonar EJ, Sweet MB. Cellular hypersensitivity in rheumatoid arthritis, ankylosing spondylitis, and anterior non-granulomatous uveitis. Arthritis Rheum 1976;19:539-44.
92. Siegert CE, Daha MR, Halma C, van der Voort EA, Breed veld FC. IgG and IgA autoantibodies to Clq in systemic and renal diseases. Clin Exp Rheumacol 1992;10:19-23.
93. Austin AK, Hobbs RN, Andersen JC, Butler RC, Ashton BA. Humoral immunity to link protein in patients with inflammatory joint disease, osteoarthritis, and in non-arthritic controls. Ann Rheum Dis 1988;47;886-92.
94. Stuart JM, Postlethwaite AE, Townes AS, Rang AH. Cell-mediated immunity to collagen and collagen alpha chains in rheumatoid arthritis and other rheumatic diseases. AmJ Med 1980;69:13-18.
95. Smolen JS, Menzel EJ, Scherak O, Kojer M, Kolarz G, Steffen C, et al. Lymphocyte transformation to denatured type I collagen and B lymphocyte alloantigens in rheumatoid arthritis. Arthritis Rheum 1980;23:424-31.
96. Clague RB, Shaw MJ, Holt PJ. Incidence of serum antibodies to native type I and type II collagens in patients with inflammatory arthritis. Ann Rheum Dis 1980;39:201-6.
97. Clague RB, Shaw MJ, Holt PJ. Incidence and correlation between serum IgG and IgM antibodies to native type II collagen in patients with chronic inflammatory arthritis. Ann Rheum Dis 1981;40:6-10.
98. Rosenberg AM, Hunt DW, Petty RE. Antibodies to native and denatured type II collagen in children with rheumatic diseases. J Rheumatol 1984;11:425-31.
99. Gao XM, Wordsworth P, McMichael A. Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur J Immunol 1994; 24:1665-70.
100. Borg AA, Nixon NB, Dawes PT, Mattey DL. Increased IgA antibodies to cytokeratins in the spondyloarthropathies. Ann Rheum Dis 1994;53:391-5.
101. Locht H, Peen E, Skogh T. Antineutrophil cytoplasmic antibodies in reactive arthritis. J Rheumatol 1995;22: 2304-6.
102. De Keyser F, Mielants H, Praet J, Goemaere S, Veys EM. Changes in antinuclear serology in patients with spondylarthropathy under sulphasalazine treatment. Br J Rheumatol 1993;32:521.
103. Saraux A, de Saint Pierre V, Baron D, Valls I, Koreichi A, Youinou PXLGP. The antiperinuclear factor in spondylarthropathies. Br J Rheumatol 1995;34:912-14.
104. Sondag-Tschroots TR, Aaij C, Smit JW, Feltkamp TE. The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis 1979;38:248-51.
105. Youinou P, Le Goff P, Dumay A, Lejong A, Fauquert PXJJ. The antiperinuclear factor I. Clinical and serologie associations. Clin Exp Rheumatol 1990;8:259-64.
106. MacSween RN, Goudie RB, Anderson JR, Armstrong E, Murray MA, Mason DKXJM, et al. Occurrence of antibody to salivary duct epithelium in Sjogren's disease, rheumatoid arthritis, and other arthritides. A clinical and laboratory study. Ann Rheum Dis 1967;26:402-11.
107. Blake DR, McGregor AM, Stansfield E, Smith BR. Antithyroid-antibody activity in the snyovial fluid of patients with various arthritides. Lancet 1979;ii:224-6.